Novel ARPNPs are delivered to tumors in response to GSH release, downregulation of PFKFB4 helps to inhibit the SRC3/Akt/mTOR pathway, and combined with rapamycin shows the potential to induce tumor autophagy, in situ tumor destruction and tumor immune activation. Here, MTOR is linked to neoplasm.